Use of Economic Evaluation in Decision Making Evidence and Recommendations for Improvement

被引:5
|
作者
Simoens, Steven [1 ]
机构
[1] Katholieke Univ Leuven, Res Ctr Pharmaceut Care & Pharmacoecon, B-3000 Louvain, Belgium
关键词
HEALTH TECHNOLOGY-ASSESSMENT; COST-EFFECTIVENESS; CLINICAL-EXCELLENCE; PHARMACEUTICAL CARE; NATIONAL-INSTITUTE; TASK-FORCE; INFORMATION; EUROPE; GROWTH; NICE;
D O I
10.2165/11538120-000000000-00000
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Information about the value for money of a medicine as derived from an economic evaluation can be used for decision-making purposes by policy makers, healthcare payers, healthcare professionals and pharmaceutical companies. This article illustrates the use of economic evaluation by decision makers and formulates a number of recommendations to enhance the use of such evaluations for decision-making purposes. Over the last decades, there has been a substantial increase in the number of economic evaluations assessing the value for money of medicines. Economic evaluation is used by policy makers and healthcare payers to inform medicine pricing/reimbursement decisions in more and more countries. It is a suitable tool to evaluate medicines and to present information about their value for money to decision makers in a familiar format. In order to fully exploit the use of economic evaluation for decision-making purposes, researchers need to take care to conduct such economic evaluations according to methodologically sound principles. Additionally, researchers need to take into account the decision-making context. They need to identify the various objectives that decision makers pursue and discuss how decision makers can use study findings to attain these objectives. These issues require further attention from researchers, policy makers, healthcare payers, healthcare professionals and pharmaceutical companies with a view to optimizing the use of economic evaluation in decision making.
引用
收藏
页码:1917 / 1926
页数:10
相关论文
共 50 条
  • [11] Incorporating economic evaluation into immunization decision making in Canada: a workshop
    Langley, Joanne M.
    Krahn, Murray
    Husereau, Don
    Spika, John
    Fisman, David N.
    Chit, Ayman
    Van Exan, Rob
    EXPERT REVIEW OF VACCINES, 2014, 13 (11) : 1291 - 1296
  • [12] Economic Evaluation Seeks Threshold to Support Decision-making
    Garcia-Lorenzo, Borja
    Vallejo-Torres, Laura
    del Mar Trujillo-Martin, Maria
    Perestelo-Perez, Lilisbeth
    Valcarcel-Nazco, Cristina
    Serrano Aguilar, Pedro
    REVISTA ESPANOLA DE SALUD PUBLICA, 2015, 89 (06): : 537 - 544
  • [13] Health economic decision-making: a comparison between UK and Spain
    Corbacho, Belen
    Luis Pinto-Prades, Jose
    BRITISH MEDICAL BULLETIN, 2012, 103 (01) : 5 - 20
  • [14] Economic evaluation in the health care decision making process: The case of England
    Castillo-Laborde, Carla
    REVISTA MEDICA DE CHILE, 2010, 138 : 103 - 107
  • [15] DISCOUNTING AND DECISION MAKING IN THE ECONOMIC EVALUATION OF HEALTH-CARE TECHNOLOGIES
    Claxton, Karl
    Paulden, Mike
    Gravelle, Hugh
    Brouwer, Werner
    Culyer, Anthony J.
    HEALTH ECONOMICS, 2011, 20 (01) : 2 - 15
  • [16] The use of economic evaluation in CAM: an introductory framework
    Ford, Emily
    Solomon, Daniela
    Adams, Jon
    Graves, Nicholas
    BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2010, 10
  • [17] The Evaluation and Use of Economic Evidence to Inform Cancer Drug Reimbursement Decisions in Canada
    Yong, Jean H. E.
    Beca, Jaclyn
    Hoch, Jeffrey S.
    PHARMACOECONOMICS, 2013, 31 (03) : 229 - 236
  • [18] EVIDENCE, VALUES, AND DECISION MAKING
    Rawlins, Michael D.
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2014, 30 (02) : 233 - 238
  • [19] Economic Evaluation in Ethiopian Healthcare Sector Decision Making: Perception, Practice and Barriers
    Zegeye, Elias Asfaw
    Mbonigaba, Josue
    Kaye, Sylvia Blanche
    Wilkinson, Thomas
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2017, 15 (01) : 33 - 43
  • [20] A Call for a Reform of the Influenza Immunization Program in Mexico: Epidemiologic and Economic Evidence for Decision Making
    Tapia-Conyer, Roberto
    Betancourt-Cravioto, Miguel
    Montoya, Alejandra
    Falcon-Lezama, Jorge Abelardo
    Alfaro-Cortes, Myrna Maria
    Saucedo-Martinez, Rodrigo
    VACCINES, 2021, 9 (03)